<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02566590</url>
  </required_header>
  <id_info>
    <org_study_id>72083</org_study_id>
    <nct_id>NCT02566590</nct_id>
  </id_info>
  <brief_title>Preventing the Loss of Muscle and Function in Hospitalized Older Adults</brief_title>
  <official_title>Preventing the Loss of Muscle and Function in Hospitalized Older Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      One third of independent older adults over the age of 65y will be hospitalized for an acute&#xD;
      medical illness, injury, or operative procedure. Unfortunately, 50% of these older adults&#xD;
      will experience functional decline during their hospital stay from the amount of time they&#xD;
      are physically inactive and in bed. Following discharge, the functional deficits can persist&#xD;
      for months and in many instances never return to pre-hospitalization levels thus compounding&#xD;
      morbidity, health care costs and dying. A classic consequence of short-term bed rest in older&#xD;
      adults is the significant loss in skeletal muscle mass which underlies the accelerated leg&#xD;
      strength deficits. The investigator has shown that an important mechanism of skeletal muscle&#xD;
      loss is the inability of nutrients to stimulate a normal muscle protein synthesis response; a&#xD;
      process highly regulated by the mammalian target of rapamycin signaling pathway (mTOR) and&#xD;
      amino acid transporters. Day to day maintenance of force generating muscle tissue is dictated&#xD;
      by anabolic stimulation from muscle contraction and essential amino acid ingestion.&#xD;
      Therefore, anabolic interventions such as neuromuscular electrical stimulation (NMES) and&#xD;
      high quality protein supplementation that contains a high proportion of essential amino acids&#xD;
      (whey protein) may be promising approach to maintain leg muscle mass and strength in&#xD;
      hospitalized older adults and prevent the long term consequences of repeated periods of&#xD;
      short-term physical inactivity. The purpose of this study is to test in older adults if the&#xD;
      combination of NMES and protein supplementation is capable of preserving muscle mass and&#xD;
      strength and maintaining muscle nutrient anabolic sensitivity during bed rest. The&#xD;
      investigators current hypotheses are that daily NMES and protein supplementation during&#xD;
      5-days of bed rest in older adults will: 1) preserve lower extremity muscle mass and strength&#xD;
      and 2) maintain muscle nutrient anabolic sensitivity as measured by mTOR signaling and amino&#xD;
      acid transporter expression. The long term goal is to utilize this inpatient preventative&#xD;
      therapeutic approach in a clinical setting in which muscle mass and strength deficits are&#xD;
      profound (e.g., intensive care patients).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A majority of older adults experience repeated periods of physical inactivity during acute&#xD;
      illnesses, injuries or after an operative procedure. Following discharge from the hospital,&#xD;
      daily activities are adversely impacted. Infirmity follows repeated periods of inactivity&#xD;
      (termed &quot;catabolic hits&quot;) that can occur over an older adults' lifespan and lead to a&#xD;
      downward spiral of potentially irrecoverable deficits in physical function resulting in&#xD;
      increased health care costs, loss of independence, and premature death. The hallmark sign of&#xD;
      short-term physical inactivity in older adults is the rapid deterioration of skeletal muscle&#xD;
      mass and strength. Understandably, little attention is placed on physical function during&#xD;
      these requisite periods of inactivity as the medical management and/or postoperative&#xD;
      recuperation is the focus. However, the muscle deficits that follow as a result of acute&#xD;
      hospitalization can have profound long-term consequences.&#xD;
&#xD;
      Muscle contraction and essential amino acids are powerful independent anabolic stimuli and&#xD;
      fundamental to maintain skeletal muscle mass and strength. The primary mechanism of disuse&#xD;
      atrophy during short-term bed rest in older adults is the reduced acute nutrient stimulation&#xD;
      of muscle protein synthesis regulated by the mammalian target of rapamycin (mTOR) signaling&#xD;
      pathway and amino acid transporter expression (i.e., LAT1). Intervening with essential amino&#xD;
      acid supplements can maintain some muscle function in older adults during bed rest, but it&#xD;
      does not preserve muscle mass. Neuromuscular electrical stimulation (NMES) as a muscle&#xD;
      intervention is also feasible, but alone is not a panacea. NMES has recently been shown to&#xD;
      acutely stimulate protein synthesis in ambulatory older adults with diabetes and attenuate&#xD;
      some loss in muscle mass in critically ill patients. The investigator suggests that,&#xD;
      together, daily NMES, and a high quality protein source of EAAs (PRO), can be a potent&#xD;
      two-pronged approach to preserve the loss of muscle and strength in older adults confined to&#xD;
      short-term bed rest. The goal is to test if the combination of NMES and PRO will maintain&#xD;
      muscle mass, strength, nutrient-induced mTOR signaling and amino acid transporter expression&#xD;
      in older adults during bed rest. The central hypothesis for this project which will support&#xD;
      this next step is that a daily combination of NMES and PRO in older adults experiencing bed&#xD;
      rest will preserve: 1) leg muscle mass and knee extensor strength and 2) muscle anabolic&#xD;
      sensitivity in response to acute nutrient ingestion, as measured by mTOR signaling and LAT1&#xD;
      expression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Percent Change in Bilateral Thigh Lean Mass Density (Grams) as Measured by DEXA Scan Will be Compared Between Baseline and After 5-days of Bed Rest</measure>
    <time_frame>Baseline and after 5-days of Bed rest</time_frame>
    <description>Thigh lean mass (grams) will be measured by DEXA scan at baseline and after 5-days of bed rest. The change in thigh lean mass will be calculated between these two time points. This outcome will be measured for the Control and the NMES + PRO groups.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Muscular Atrophy</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will complete bed rest but will receive a non-protein placebo supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NMES + PRO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive daily treatment with neuromuscular electrical stimulation (NMES) and daily supplements of a protein drink.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NMES</intervention_name>
    <description>device is used to stimulate muscle contraction in the legs of the patient. The intervention will be used 3 times a day during bed rest.</description>
    <arm_group_label>NMES + PRO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Protein</intervention_name>
    <description>supplement will used to enhance muscle anabolism. The intervention will be provided 3 times a day during bed rest.</description>
    <arm_group_label>NMES + PRO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>non-protein placebo supplement</intervention_name>
    <description>supplement will be used as a placebo to control participants. The supplement will be provided 3x a day during bed rest.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Age between 60-85 yrs Ability to sign informed consent Montreal cognitive assessment (MOCA)&#xD;
        exam score â‰¥26 Free-living, prior to admission&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Cardiac abnormalities considered exclusionary by the study physician (e.g., CHF, CAD,&#xD;
             right-to-left shunt)&#xD;
&#xD;
          2. Uncontrolled endocrine or metabolic disease (e.g., hypo/hyperthyroidism, diabetes)&#xD;
&#xD;
          3. GFR &lt;65 mL/min/1.73m2 or evidence of kidney disease or failure&#xD;
&#xD;
          4. Vascular disease or risk factors of peripheral atherosclerosis. (e.g., uncontrolled&#xD;
             hypertension, obesity, diabetes, hypercholesterolemia &gt; 250 mg/dl, claudication or&#xD;
             evidence of venous or arterial insufficiency upon palpitation of femoral, popliteal&#xD;
             and pedal arteries)&#xD;
&#xD;
          5. Risk of DVT including family history of thrombophilia, DVT, pulmonary emboli,&#xD;
             myeloproliferative diseases including polycythemia (Hb&gt;18 g/dL) or thrombocytosis&#xD;
             (platelets&gt;400x103/mL), and connective tissue diseases (positive lupus anticoagulant),&#xD;
             hyperhomocysteinemia, deficiencies of factor V Leiden, proteins S and C, and&#xD;
             antithrombin III&#xD;
&#xD;
          6. Use of anticoagulant therapy (e.g., Coumadin, heparin)&#xD;
&#xD;
          7. Elevated systolic pressure &gt;150 or a diastolic blood pressure &gt; 100&#xD;
&#xD;
          8. Implanted electronic devices (e.g., pacemakers, electronic infusion pumps,&#xD;
             stimulators)&#xD;
&#xD;
          9. Cancer or history of successfully treated cancer (less than 1 year) other than basal&#xD;
             cell carcinoma&#xD;
&#xD;
         10. Currently on a weight-loss diet or body mass index &gt; 30 kg/m2&#xD;
&#xD;
         11. Inability to abstain from smoking for duration of study&#xD;
&#xD;
         12. A history of &gt; 20 pack per year smoking&#xD;
&#xD;
         13. HIV or hepatitis B or C*&#xD;
&#xD;
         14. Recent anabolic or corticosteroids use (within 3 months)&#xD;
&#xD;
         15. Subjects with hemoglobin or hematocrit lower than accepted lab values&#xD;
&#xD;
         16. Agitation/aggression disorder (by psychiatric history and exam)&#xD;
&#xD;
         17. History of stroke with motor disability&#xD;
&#xD;
         18. A recent history (&lt;12 months) of GI bleed&#xD;
&#xD;
         19. Depression [&gt;5 on the 15 items Geriatric Depression Scale (GDS)]&#xD;
&#xD;
         20. Alcohol or drug abuse&#xD;
&#xD;
         21. Exercise training (&gt;1 session of moderate to high intensity aerobic or resistance&#xD;
             exercise/week)&#xD;
&#xD;
         22. Liver disease (AST/ALT 2 times above the normal limit, hyperbilirubinemia)&#xD;
&#xD;
         23. Respiratory disease (acute upper respiratory infection, history of chronic lung&#xD;
             disease with resting oxygen saturation &lt;97% on room air)&#xD;
&#xD;
         24. Any other condition or event considered exclusionary by the PI and faculty physician&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Micah Drummond, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>September 23, 2015</study_first_submitted>
  <study_first_submitted_qc>October 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2015</study_first_posted>
  <results_first_submitted>October 9, 2018</results_first_submitted>
  <results_first_submitted_qc>March 28, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 16, 2019</results_first_posted>
  <last_update_submitted>April 15, 2019</last_update_submitted>
  <last_update_submitted_qc>April 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Micah Drummond</investigator_full_name>
    <investigator_title>Ph.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>Participants will complete bed rest but will receive a non-protein placebo supplement&#xD;
non-protein placebo supplement: supplement will be used as a placebo to control participants. The supplement will be provided 3x a day during bed rest.</description>
        </group>
        <group group_id="P2">
          <title>NMES + PRO</title>
          <description>Participants will receive daily treatment with neuromuscular electrical stimulation (NMES) and daily supplements of a protein drink.&#xD;
NMES: device is used to stimulate muscle contraction in the legs of the patient. The intervention will be used 3 times a day during bed rest.&#xD;
Protein: supplement will used to enhance muscle anabolism. The intervention will be provided 3 times a day during bed rest.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>Participants will complete bed rest but will receive a non-protein placebo supplement&#xD;
non-protein placebo supplement: supplement will be used as a placebo to control participants. The supplement will be provided 3x a day during bed rest.</description>
        </group>
        <group group_id="B2">
          <title>NMES + PRO</title>
          <description>Participants will receive daily treatment with neuromuscular electrical stimulation (NMES) and daily supplements of a protein drink.&#xD;
NMES: device is used to stimulate muscle contraction in the legs of the patient. The intervention will be used 3 times a day during bed rest.&#xD;
Protein: supplement will used to enhance muscle anabolism. The intervention will be provided 3 times a day during bed rest.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69" spread="6.7"/>
                    <measurement group_id="B2" value="69" spread="5.4"/>
                    <measurement group_id="B3" value="69" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Percent Change in Bilateral Thigh Lean Mass Density (Grams) as Measured by DEXA Scan Will be Compared Between Baseline and After 5-days of Bed Rest</title>
        <description>Thigh lean mass (grams) will be measured by DEXA scan at baseline and after 5-days of bed rest. The change in thigh lean mass will be calculated between these two time points. This outcome will be measured for the Control and the NMES + PRO groups.</description>
        <time_frame>Baseline and after 5-days of Bed rest</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Participants will complete bed rest but will receive a non-protein placebo supplement&#xD;
non-protein placebo supplement: supplement will be used as a placebo for control participants. The supplement will be provided 3x a day during bed rest.</description>
          </group>
          <group group_id="O2">
            <title>NMES + PRO</title>
            <description>Participants will receive daily treatment with neuromuscular electrical stimulation (NMES) and daily supplements of a protein drink.&#xD;
NMES: device is used to stimulate muscle contraction in the legs of the patient. The intervention will be used 3 times a day during each day of bed rest.&#xD;
Protein (PRO): supplement will used to enhance muscle anabolism. The intervention will be provided 3 times a day during each day of bed rest.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percent Change in Bilateral Thigh Lean Mass Density (Grams) as Measured by DEXA Scan Will be Compared Between Baseline and After 5-days of Bed Rest</title>
          <description>Thigh lean mass (grams) will be measured by DEXA scan at baseline and after 5-days of bed rest. The change in thigh lean mass will be calculated between these two time points. This outcome will be measured for the Control and the NMES + PRO groups.</description>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.845" spread="0.883"/>
                    <measurement group_id="O2" value="-0.249" spread="1.189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>Participants will complete bed rest but will receive a non-protein placebo supplement&#xD;
non-protein placebo supplement: supplement will be used as a placebo to control participants. The supplement will be provided 3x a day during bed rest.</description>
        </group>
        <group group_id="E2">
          <title>NMES + PRO</title>
          <description>Participants will receive daily treatment with neuromuscular electrical stimulation (NMES) and daily supplements of a protein drink.&#xD;
NMES: device is used to stimulate muscle contraction in the legs of the patient. The intervention will be used 3 times a day during bed rest.&#xD;
Protein: supplement will used to enhance muscle anabolism. The intervention will be provided 3 times a day during bed rest.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Micah Drummond</name_or_title>
      <organization>University of Utah</organization>
      <phone>8015877764</phone>
      <email>micah.drummond@hsc.utah.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

